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OBSTETRICSDetection of triploid, molar, and vanishing
twin pregnancies by a single-nucleotide
polymorphismebased noninvasive
prenatal test
Kirsten J. Curnow, PhD; Louise Wilkins-Haug, PhD, MD; Allison Ryan, PhD;
Eser Kırkızlar, PhD; Melissa Stosic, MS; Megan P. Hall, PhD; Styrmir Sigurjonsson, PhD;
Zachary Demko, PhD; Matthew Rabinowitz, PhD; Susan J. Gross, MDOBJECTIVE: We sought to determine the ability of single-nucleotide twin, 48.7% were viable twin, 5.3% were diandric triploids, and 3.9%
polymorphismebased noninvasive prenatal testing (NIPT) to identify
triploid, unrecognized twin, and vanishing twin pregnancies.
STUDY DESIGN: The study included 30,795 consecutive reported
clinical cases received for NIPT for fetal whole-chromosome aneu-
ploidies; known multiple gestations were excluded. Cell-free DNA was
isolated from maternal blood samples, amplified via 19,488-plex
polymerase chain reaction, and sequenced. Sequencing results
were analyzed to determine fetal chromosome copy number and to
identify the presence of additional fetal haplotypes.
RESULTS: Additional fetal haplotypes, indicative of fetal triploidy, van-
ishing twin, or undetected twin pregnancy, were identified in 130
(0.42%) cases. Clinical confirmation (karyotype for singleton pregnan-
cies, ultrasound for multifetal pregnancies) was available for 58.5% (76/
130) of cases. Of the 76 cases with confirmation, 42.1% were vanishingFrom Natera, San Carlos, CA (Drs Curnow, Ryan, Kırkızlar, Hall, Sigurjonsso
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One pregnancy had other indications suggesting triploidy but lacked
karyotype confirmation. Of the 5 vanishing twin cases with a known date
of demise, 100% of losses occurred in the first trimester; up to 8 weeks
elapsed between loss and detection by NIPT.
CONCLUSION: This single-nucleotide polymorphismebased NIPT
successfully identified vanished twin, previously unrecognized twin,
and triploid pregnancies. As vanishing twins are more likely to be
aneuploid, and undetected residual cell-free DNA could bias NIPT
results, the ability of this method to identify additional fetal haplotypes
is expected to result in fewer false-positive calls and prevent incorrect
fetal sex calls.
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JANUARY 2015 Amemethods.1-12 NIPT noninvasively de-
termines fetal chromosome copy num-
ber by interrogating cfDNA isolated
from maternal plasma, with the fetus
contributing anywhere from <2% to
>30% of the total cfDNA.3,7,13 Other
NIPT approaches use quantitative
“counting” methods where fetal chro-
mosome copy number is determined by
comparing the absolute number of
sequence reads from the chromosome(s)
of interest (eg, chromosome 21) to
reference chromosome(s), and inferring
fetal trisomy when this ratio is above a
predetermined threshold. This approach
cannot determine the source of DNA
(fetal or maternal) and is therefore un-
able to detect additional fetal haplotypes
associated with triploidy or vanishing
twins. Vanishing twins were reported to
account for 15% of false positives in arican Journal of Obstetrics& Gynecology 79.e1
Research Obstetrics ajog.orgrecent counting-based NIPT study.14
This likely results in unnecessary inva-
sive prenatal testing. A more recent
approach using a single-nucleotide
polymorphism (SNP)-based method
along with sophisticated informatics can
resolve this potential source of false-
positive results. This approach iden-
tiﬁes the presence of additional fetal
haplotypes, indicative of a triploid or
dizygotic multifetal pregnancy, and de-
termines parental origin.10,12
Using the SNP-based approach, the
prevalence of cases found to have addi-
tional fetal haplotypes within 30,795
consecutive cases undergoing routine
clinical NIPT was determined, and is
reported here. Clinical follow-up of
these cases is also described.
MATERIALS AND METHODS
Patients
The current study included all samples
from participating centers received for
commercial testing from March 1,
through Nov. 30, 2013, that received an
NIPT result. This study received a notiﬁ-
cation of exempt determination from an
institutional review board (Ethical and
Independent Review Services, no. 14064-
01). All samples were analyzed at Natera’s
Clinical Laboratory Improvement Acte
certiﬁed and College of American
Pathologistseaccredited laboratory in
San Carlos, CA. Analysis was performed
for all samples on chromosomes 13, 18,
21, X, and Y, and included detection of
trisomy 21, trisomy 18, trisomy 13,
monosomy X, sex chromosome abnor-
malities (47,XXX/XXY/XYY), fetal sex,
and additional fetal haplotypes.
Sample collection and NIPT
Maternal blood samples (>13 mL) were
collected in Streck (Omaha, NE) blood
collection tubes and processed at Natera
(San Carlos, CA) within 6 days of collec-
tion. All samples were accompanied by a
requisition form from the ordering clini-
cian, and included the following patient
information: gestational age, maternal
date of birth, maternal weight, whether it
was a multigestation pregnancy, and
whether a paternal buccal swab was
included. Ordering clinicians determined
indication(s) for testing. Cases accepted79.e2 American Journal of Obstetrics& Gynecolofor analysis were indicated as singleton
pregnancies by ordering clinicians. Results
were reported directly to the ordering
clinician or distribution partners.
Samples were considered outside of
the speciﬁcations for testing and were
not analyzed if there was insufﬁcient
blood volume or the wrong tube was
used, the sample was damaged, the
sample was received at the laboratory>6
days after collection, the gestational age
was <9 weeks, the patient used an egg
donor, or the patient had a conﬁrmed
multiple gestation.15 Testing was per-
formed on all samples with sufﬁcient
blood volume (>13 mL) as described
previously using validated laboratory
methodologies (cfDNA isolation, poly-
merase chain reaction ampliﬁcation
targeting 19,488 SNPs, high-throughput
sequencing, and analysis using the Next-
generation Aneuploidy Test Using SNPs
[NATUS] algorithm).9-12,15 Samples
were subject to a stringent set of quality-
control metrics9-13,15 before reports were
sent to ordering clinicians.
The NATUS algorithm incorporates
parental genotypic information, uses
numerous quality control metrics, and
determines a sample-speciﬁc accuracy
for each interrogated chromo-
some.9-12,15 Brieﬂy, the algorithm con-
siders parental genotypic information,
crossover frequency data, and possible
fetal chromosome copy numbers
(monosomy/disomy/trisomy) at 19,488
evaluated polymorphic loci. By
comparing the observed fetal allele dis-
tributions from the sequencing data to
the predicted distributions, the algo-
rithm determines the fetal ploidy state
with the maximum likelihood for each
interrogated chromosome; this
maximum likelihood probability is
incorporated into a risk score for
reporting purposes.15 The NATUS al-
gorithm is currently only validated to
call aneuploidy in singleton gestations.
However, the algorithm is able to deter-
mine when cfDNA sequencing results do
not match the modeled fetal copy
numbers with a high likelihood, and can
identify the presence of additional fetal
haplotypes that indicate either fetal
triploidy or the presence of an unde-
tected dizygotic multiple gestation. Thegy JANUARY 2015presence of an additional fetal haplotype
was identiﬁed when all tested chromo-
somes failed to match the disomy hy-
pothesis, and when the additional
haplotype was apparent from allele dis-
tributions. At this time, the algorithm
cannot distinguish dizygotic twin gesta-
tions from triploidy pregnancies due to
similar allele distributions (Figure 1);
therefore these are reported as a single
call. Speciﬁcally, in a euploid singleton
pregnancy, where thematernal alleles are
AA (with dimorphic alleles arbitrarily
labeled as A and B), the 2 expected fetal
genotypes include AA and AB. By
contrast, in dizygotic twin and triploid
pregnancies where the maternal alleles
are AA, there are 3 expected fetal geno-
types for both triploid (AAA, AAB, ABB)
(Figure 1, A) and dizygotic twin (AA/AA,
AA/AB, AB/AB) (Figure 1, B) pregnan-
cies. This results in equivalent B allele
distributions (0, 1, or 2 B alleles), and
very similar A allele distributions in
triploid (1, 2, or 3) and dizygotic twin (2,
3, or 4) pregnancies.
For cases with an identiﬁed additional
fetal haplotype, a report was sent to the
ordering clinician or laboratory indi-
cating that the results were consistent
with a possible triploid or vanishing twin
pregnancy, and recommending follow-
up counseling and testing; after report
delivery, a Natera genetic counselor
contacted the ordering clinician/pro-
vider to answer questions related to the
NIPT ﬁndings.
Clinical outcomes
Follow-up information on cases identi-
ﬁed with an additional fetal haplotype
was requested by telephone at regular
intervals from ordering clinicians and
partner laboratories. All information de-
tailing ultrasoundﬁndings and pregnancy
outcomes were recorded in the laboratory
follow-up database. Follow-up informa-
tion directly reported to Natera by pro-
viders was also recorded. Multifetal
pregnancies were conﬁrmed by ultra-
sound, which is consistent with how
they are clinically diagnosed in practice.
Cases were categorized as follows: (1)
“conﬁrmed vanishing twin pregnancy” if
ultrasound detected a second empty sac
or second sac containing a deceased fetus;
FIGURE 1
Additional parental haplotypes detected in vanishing twin and triploidy pregnancies
13 18 21 X 1 
0 
Fr
ac
tio
n 
of
 A
 a
lle
le
 re
ad
s 
AA 
BB 
AB 
AAA/AA (X) 
ABB 
Fetal Maternal 
AAB/AB (X) 
AAA 
ABB 
AAB 
BBB 
AAB 
BBB/BB(X) 
ABB/AB(X) 
Y 
AA(X) 
AB(X) 
BB(X) 
13 18 21 X 
1 
0 
Fr
ac
tio
n 
of
 A
 a
lle
le
 re
ad
s 
AA 
BB 
AB 
AA/AA 
AB/AB 
Fetus 1/2 Maternal 
AA/AB 
AA/AA 
AB/AB 
AA/AB 
BB/AB 
BB/BB 
AB/AB 
BB/BB 
AB/BB 
Y 
Graphical representation of sequencing data obtained from A, a paternal triploidy sample and B, a vanishing twin sample. It is important to note that this is
not how the algorithm makes copy number calls, but is one method for visualizing data. All interrogated single-nucleotide polymorphisms (SNPs) are
assumed to be dimorphic and are designated as A and B for simplicity. Briefly, for each graph, the number of A allele reads as a fraction of total reads is
plotted (y-axis) against the position of each of several thousand interrogated SNPs on chromosomes of interest (x-axis). X-axis represents the linear
position of each SNP along the chromosome, and each spot corresponds to a single SNP. As plasma cell-free DNA (cfDNA) is a mixture of fetal and
maternal cfDNA, the vertical position of each spot represents the sum of contribution of both fetal and maternal allele reads, and is a function of the fetal
fraction. To more readily visualize maternal and fetal contributions, spots are colored according to maternal genotype: SNPs for which the mother is
homozygous for the A allele (AA) are red, SNPs for which the mother is homozygous for the B allele (BB) are blue, and SNPs for which the mother is
heterozygous (AB) are green. Since the majority of plasma cfDNA is maternal in origin, spots mainly distribute according to the maternal genotype. The
contribution of fetal allele reads results in segregation into distinct clusters. Because loci targeted on the Y chromosome are homologous to loci on the X
chromosome, but differ by 1 nucleotide, probes hybridize to both chromosomes. However, targeted alleles have chromosomally distinct, nondimorphic
identities, so are not color-coded; all alleles from the X chromosome are assigned as A alleles, and all alleles from the Y chromosome are assigned as B
alleles. A, Confirmed paternal triploidy, 22.6% fetal cfDNA fraction. Position of peripheral red and blue clusters indicates additional haplotypes, as
indicated to the right of the plot. Alleles for the X chromosome are indicated (X). Presence of B alleles from the Y chromosome shifts the cluster downward,
indicating the presence of a single Y chromosome (based on distribution of reads). Together, this suggests a fetal chromosomal complement of 69,XXY.
B, Confirmed vanishing twin, 19.6% fetal cfDNA fraction. Position of peripheral red and blue clusters indicates additional haplotypes, as indicated to the
right of the plot. Presence of B alleles from the Y chromosome shifts the cluster downward, indicating the presence of a single Y chromosome (based on
distribution of reads). Together, this suggests the presence of vanishing twins, as indicated to right of plot; “Fetus 1/2” indicates genotypes of fetus 1/
fetus 2. Center green clusters only segregate and are readily visible at higher fetal fractions.
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ajog.org Obstetrics Research(2) “conﬁrmed ongoing twin pregnancy”
if ultrasound showed an ongoing and
viable twin pregnancy; (3) “conﬁrmed
fetal triploidy” if triploidy was conﬁrmed
by invasive testing or testing of products
of conception (POC); (4) “unconﬁrmed
fetal triploidy” included cases without
invasive diagnostic testing but with
ultrasound ﬁndings consistent with trip-
loidy; (5) “conﬁrmed nontriploid preg-
nancy” included cases where invasive
diagnostic testing ruled out fetal triploidy
and there was no evidence of co-twin
demise; (6) “pregnancy loss” for cases
where patients experienced spontaneous
abortion and did not obtain karyotype
conﬁrmation; or (7) “no follow-up”where follow-up information was
requested but was not received by the
time of manuscript submission.Statistical analysis
Differences in the maternal age and
gestational age between conﬁrmed
twin and conﬁrmed vanishing twin co-
horts were determined using a Mann-
Whitney rank sum test. A t test was
used to compare the fetal fraction in
conﬁrmed twin and vanishing twin
cases. SigmaPlot 12.5 (Systat Software,
San Jose, CA) was used for all statisti-
cal analyses. A P value of < .05 was
considered statistically signiﬁcant.JANUARY 2015 AmeUnless otherwise indicated, data are
presented as the mean  SD.
RESULTS
Study participants and samples
In the present cohort of 30,795 cases with
an NIPT result, 130 (0.42%) received a
report indicating the presence of addi-
tional fetal haplotypes. For the whole
cohort, themeanmaternal age was 33.6
6.1 (range, 13.0e63.0) years (Figure 2, A),
and the mean gestational age was 14.5 
4.7 (range, 9.0e40.9) weeks (Figure 2, B);
maternal age was conﬁrmed for the single
case with a maternal age >52 years. For
the 130 cases where an additional fetal
haplotype was identiﬁed by NATUS, therican Journal of Obstetrics& Gynecology 79.e3
FIGURE 2
Maternal age and gestational age histograms
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A, Maternal and B, gestational age histograms for the whole cohort. C, Maternal and D, gestational age histograms for cases with identified additional
fetal haplotypes. Although not apparent because of the scale of the Y-axis, within the whole cohort there were 8 cases with maternal ages of 49-63 years;
maternal age was confirmed for the single case with a maternal age of >52 years.
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Research Obstetrics ajog.orgmeanmaternal age was 34.3 5.7 (range,
19.0e52.0) years (Figure 2, C), and the
mean gestational age was 13.3  4.1
(range, 9.0e38.0) weeks (Figure 2, D).
While the majority of NIPTsamples were
from women at early gestational ages,
samples were received up to 40 weeks’
gestation (Figure 3); 2% (658/30,795) of
samples were from women in their third
trimester.
Clinical outcomes
Karyotype or ultrasound conﬁrmation
(karyotype for singleton pregnancies,
ultrasound for multifetal pregnancies)79.e4 American Journal of Obstetrics& Gynecolowas available for 76 (58.5%) of the 130
cases identiﬁed with additional parental
haplotypes. This included 32 (42.1%)
vanishing twin, 37 (48.7%) viable twin, 4
(5.3%) triploid pregnancies, and 3
(3.9%) nontriploid pregnancies that
lacked evidence of co-twin demise
(Table 1). For the 3 nontriploid preg-
nancies, 2 had euploid karyotypes, and 1
was shown to be a trisomy 18 fetus
(Appendix; Supplementary Table).
Multifetal pregnancies
Vanishing twin cases had a signiﬁcantly
higher median maternal age than twingy JANUARY 2015cases, 37.5 and 33.0 years, respectively
(P < .001). The median gestational age
was slightly lower in vanishing twin cases
than in twin cases, 12.1 and 13.0 weeks,
respectively (P ¼ .018). There was no
signiﬁcant difference (P¼ .686) between
the average fetal fraction of vanished
twin (11.0  3.8%) and twin (11.4 
4.3%) pregnancies. Of the 32 vanishing
twin cases, 25 (78.1%) were in the ﬁrst
trimester and 7 (21.9%) were in the
second trimester at the time of NIPT
sampling. Five cases reported an esti-
mated date of fetal demise: demise
occurred in the ﬁrst trimester in all 5
FIGURE 3
Graphical representation of time elapsed between estimated fetal demise
and detection by NIPT for 5 confirmed vanishing twin cases
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Each line indicates an individual confirmed vanishing twin case with a known estimated date of fetal
demise. The longest period between fetal demise and NIPT was 8 weeks.
NIPT, noninvasive prenatal testing.
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TABLE 1
Follow-up information on twins/
triploidy calls
All cases (n[ 130a) Value
Multifetal pregnancies
Ongoing twinb 37
Vanishing twinb 32
Singleton pregnancies
Confirmed triploidc 4
Unconfirmed triploid 1d
Confirmed nontriploid 3e
Unknown fetal no.
Pregnancy lossf 3
No follow-upg 50
a Total no. of cases with “additional fetal haplotypes”
(twins/triploidy) result at 9 wk of gestation; b Con-
firmed by ultrasound detection of multifetal preg-
nancy; c Confirmed by karyotype; d Patient had
ultrasound findings that were consistent with triploid
fetus, amniocentesis was not possible because of
oligohydramnios; e Invasive testing revealed single
euploid fetus in 2 pregnancies and single trisomy 18
fetus in 1 pregnancy; f Patient experienced sponta-
neous abortion and did not obtain karyotype confir-
mation, ultrasound was suggestive of singleton
pregnancy; g Follow-up information was not available.
Curnow. SNP-based NIPT detects vanishing twin
pregnancies. Am J Obstet Gynecol 2015.
ajog.org Obstetrics Researchcases (Figure 3). The time between
demise and NIPT sampling ranged from
2-8 weeks (Table 2).
Triploid pregnancies
All triploidy cases in this cohort were
determined to be diandric (Table 3),
indicating that in each case the addi-
tional fetal haplotype was paternal in
origin. Fetal sex was determined for all
triploidy cases by analysis of fetal sex
chromosome copy numbers; the fetal
karyotype matched the fetal sex deter-
mined by NIPT for all 3 triploidy cases
where karyotype speciﬁcs were commu-
nicated during follow-up (Table 3).
For triploidy cases 1, 2, and 4 detailed in
Table 3, the pregnancies spontaneously
aborted and karyotype conﬁrmation
was obtained from the POC; during
clinical follow-up, 2 of these cases were
reported as partial mole pregnancies. For
triploidy cases 3 and 5 (Table 3), clinical
evaluation identiﬁed large placentas
and oligohydramnios in both cases.
COMMENT
This SNP-based NIPT approach identi-
ﬁed previously undetected twin andtriploid pregnancies in women undergo-
ing routine prenatal screening. This
method was previously validated for
detecting fetal trisomy 21, trisomy 18,
trisomy 13, monosomy X, and sex chro-
mosome trisomies in singleton pregnan-
cies, as well as additional fetal haplotypes
indicating twin or triploid pregnancies.9-
12 This is the ﬁrst report detailing the
clinical outcomes following NIPT iden-
tiﬁcation of additional fetal haplotypes in
a large general screening population.
Because this SNP-based method ana-
lyzes polymorphic loci, incorporates
genotypic information, and does not
require a reference chromosome, it is
uniquely able to detect the presence of
additional fetal haplotypes associated
with dizygotic twins and triploidy.
However, this method currently does not
distinguish between these possibilities.
Ultrasound examination should readily
distinguish between an ongoing twin
and a singleton pregnancy, and may
reveal the presence of a vanished twin. A
conﬁrmed ongoing twin pregnancy may
warrant close monitoring of the preg-
nancy, as twin pregnancies involve a
unique set of complications16,17; theJANUARY 2015 Ameadditional haplotype merely suggests
dizygotic twins. In the case of a
conﬁrmed singleton pregnancy with
NIPT-identiﬁed additional haplotypes,
options include repeat NIPT, taking a
wait-and-see approach, or follow-up
diagnostic testing to rule out triploidy;
invasive testing should be carefully
considered in light of other indications
given the inherent risks to mother and
baby.18 Where ultrasound indicates a
singleton pregnancy and where triploidy
indications are lacking, or where invasive
testing ruled out triploidy, the possibility
of early and undetected co-twin demise
cannot be ruled out. Most vanishings
occur in the ﬁrst trimester,19 so clinical
detection is largely dependent on
whether a patient receives an early ul-
trasound and the time of fetal demise.
Thus, for patients electing NIPT, an ul-
trasound may provide helpful informa-
tion to assess fetal number and detect the
presence of a vanishing twin or fetal
triploidy.rican Journal of Obstetrics& Gynecology 79.e5
TABLE 2
Case details for confirmed vanishing twin cases
Case
GA at
demise, wk
GA at
NIPT, wk
Time from demise
to NIPT, wk Fetal fraction
1 8.0 10.3 2.3 11.7%
2 7.1 10.4 3.3 4.6%
3 8.6 12.6 4.0 12.8%
4 8.0 14.7 6.7 11.8%
5 7.0 15.0 8.0 8.1%
GA at estimated date of co-twin demise and at time of sample collection for NIPT, elapsed time between estimated demise and
NIPT sampling, and fetal fraction for confirmed vanishing twin cases where clinical follow-up provided estimated date of fetal
demise.
GA, gestational age; NIPT, noninvasive prenatal testing.
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is clinically important. Speciﬁcally,
chromosomal abnormalities, which are
common in vanished twins, are likely to
generate false-positive results when us-
ing methods that can only assess total
DNA and are unable to detect additional
haplotypes. Indeed, 2 recent studies us-
ing counting-based methods attributed a
signiﬁcant proportion of false positives
to vanishing twins: in one, 15% of
NIPT false-positive results were shown
to involve vanished twins,14 and in a
second study 33% (1/3) of trisomy 21
false positives were attributed to van-
ishing twins.20 Additionally, a vanished
twin with discordant fetal sex may
lead to the incorrect NIPT-basedTABLE 3
Case details for triploidy cases
Case
NIPT findings
Fetal fraction
Parent of
origina
Predic
sex
1 5.1% Diandric XXX
2 11.4% Diandric XXY
3 22.6% Diandric XXY
4 12.2% Diandric XXY
5 6.4% Diandric XXX
a Parent of origin of extra fetal haplotype, as determined by NIPT;
clinical follow-up; c Amniocentesis was not possible because
with triploid fetus.
N/A, not available; NIPT, noninvasive prenatal testing.
Curnow. SNP-based NIPT detects vanishing twin pregnanc
79.e6 American Journal of Obstetrics& Gynecoloidentiﬁcation of fetal sex when
compared to ultrasound (eg, a female
fetus where there is a male vanished twin
may be identiﬁed as male via NIPT).
Both circumstances lead to parental
anxiety and may escalate to unnecessary
invasive testing, which carries with it a
small but real risk of harm tomother and
fetus.18
Similarly, identiﬁcation of triploid
pregnancies is beneﬁcial because of the
substantial clinical implications for pa-
tients. Triploidy results in severe fetal
abnormalities and elevated risks for
spontaneous abortion, preeclampsia,
excessive postdelivery bleeding, and
gestational trophoblastic neoplasia.21,22
As such, timely detection of triploidClinical outcomes
ted
Result Karyotype
Triploidy 69,XXX
Triploidy 69,XXY
Triploidy N/Ab
Triploidy 69,XXY
Unconfirmed
triploidyc
b Detailed karyotype findings were not communicated during
of oligohydramnios, but ultrasound findings were consistent
ies. Am J Obstet Gynecol 2015.
gy JANUARY 2015cases may alter clinical management.
The incorporation of parental genotypic
information allowed for determination
of parental origin; all cases in this study
were diandric triploidy. Clinically, these
cases would likely present as partial
molar pregnancies, which would be at
risk for gestational trophoblastic
neoplasia and choriocarcinoma, a ma-
lignant trophoblastic cancer.23-25
Digynic triploidies should also be
detectable with this SNP-based method.
However, these pregnancies present with
very small, nonmolar placentas,26 which
is correlated with decreased fetal cfDNA
fractions and complicates detection us-
ing NIPT.10 However, previous studies
showed that an “extremely low fetal
fraction” per se increased the risk of fetal
chromosomal aneuploidy, including
digynic triploidy.10,12
The prevalence of twin pregnancies is
approximately 1 in 30 births,27,28 with
vanishing twins occurring in approxi-
mately 30% of early diagnosed twin
pregnancies.29-33 This is substantially
higher than for triploid pregnancies,
which occur in approximately 1 in 2000
pregnancies at 12 weeks of gestation,
when many women undergo NIPT.34,35
Thus, the substantially greater possibil-
ity of a vanishing twin pregnancy (or
unrecognized multiple gestation) should
not be overlooked upon a screen-
positive result.
The increased incidence of twinning
in developed countries, a reﬂection of
the progressive rise in the average
maternal age at the time of concep-
tion36,37 and increasing utilization of
assisted reproductive technology
(ART),27 has important clinical impli-
cations for prenatal screening. Specif-
ically, twinning rates are higher in
women using ART, so the proportion of
vanishing twin pregnancies is also likely
higher. Indeed, 9% of conceptions using
intracytoplasmic sperm injection resul-
ted in vanishing twin pregnancies.38
However, it is unclear how many
women in this cohort used ART; the
number of cases found to involve a
vanishing twin was 0.18% (additional
fetal haplotypes were identiﬁed in 0.42%
of the 30,795 cases, and of those cases
with clinical follow-up, 42.7% were
ajog.org Obstetrics Researchvanishing twin pregnancies, for 0.42%
42.7%). It may be reasonable to assume
that the rate of aneuploidy among van-
ished twins is similar to that found in
analysis of POC samples, which was re-
ported to be about 60%.39,40 This im-
plies that approximately 0.11% of NIPT
cases involve a chromosomally abnormal
vanishing twin. As this is the same order
of magnitude as NIPT false-positive
rates, it is not surprising that vanishing
twins have been found to be responsible
for a signiﬁcant proportion of false
positives in some studies14,20 using NIPT
methods that cannot detect vanished
twins. Determining a more precise cor-
relation between vanishing twins and
aneuploidy as well as fetal fraction is an
important area for ongoing research, but
is beyond the scope of this present study.
In this cohort, the average maternal
age was signiﬁcantly higher in conﬁrmed
vanishing twin than in conﬁrmed
ongoing twin pregnancies, which is
consistent with the increased risk for
fetal aneuploidies associated with
increasing maternal age. This suggests
that fetal aneuploidy may underlie the
losses in the vanishing twin cohort.
Vanishing twin and ongoing twin preg-
nancies could not be distinguished by
fetal fractions. Of note, algorithm esti-
mates of fetal fraction are based on a
methodology validated in singleton
pregnancies, and have not been inde-
pendently validated in twin pregnancies.
Ongoing clinical studies are focused on
validating aneuploidy risk determina-
tion in multifetal pregnancies using this
SNP-based technology.
It is unclear how long after demise the
placenta from a vanished twin may
contribute fetal cfDNA to maternal cir-
culation. This is likely governed by the
rate of placental tissue autolysis and the
gestational age of the fetus at the time of
demise. Studies in singleton pregnancies
have shown that fetal cfDNA levels were
5-fold higher in women at the time of
clinical recognition of spontaneous
abortion than in women of the same
gestational age with an ongoing preg-
nancy,41 and remained elevated for at
least 7 days after spontaneous abortion
diagnosis.42 Further, this effect was
more pronounced in chromosomallyabnormal spontaneous abortions than in
spontaneous abortions with a normal
karyotype.42 As such, it is quite possible
that in a multifetal pregnancy there may
be a similarly increased cfDNA contri-
bution from a vanished twin immedi-
ately following the loss, thus
compromising cfDNA screening results
for the viable twin. In the results re-
ported here, fetal cfDNA from a van-
ished twin was detectable for up to 8
weeks following co-twin demise. Thus,
there is the potential for vanished twins
to inﬂuence NIPT results long after co-
twin demise.
A limitation of this study was incom-
plete follow-up, reﬂecting the reality that
many patients do not receive a ﬁrst-
trimester ultrasound or may transfer
care. Nevertheless, where data were re-
ported, the presence of additional fetal
haplotypes determined by NIPT was
conﬁrmed in the vast majority of cases
by ultrasound detection of a multifetal
pregnancy or karyotype conﬁrmation of
fetal triploidy.
This SNP-based NIPT identiﬁed van-
ishing twin, unrecognized ongoing twin,
and triploid pregnancies. Identiﬁcation
of partial (triploidy) and complete molar
pregnancies is important because of the
substantial clinical implications for pa-
tients, including the risk for gestational
trophoblastic neoplasia and choriocar-
cinoma. As vestigial placental tissue from
a lost twin can contribute fetal cfDNA to
maternal circulation for weeks post-
demise, identiﬁcation of vanishing twin
pregnancies is critical to avoid incorrect
NIPT results and subsequent unnec-
essary invasive procedures when non-
SNP-based NIPTmethods are used.
Conclusion
The principal ﬁnding of this study was
that SNP-based NIPT can uniquely
detect triploidy and unrecognized mul-
tifetal pregnancies, including vanishing
twins, within a general screening popu-
lation. Clinical outcomes revealed that
the majority of these cases were unrec-
ognized multifetal pregnancies, ongoing
or vanishing twins, with a small number
of triploid pregnancies also detected.
The ability to detect vanishing twin
pregnancies is clinically important as itJANUARY 2015 Amewill reduce the number of false-positive
results and thereby reduce unnecessary
invasive diagnostic procedures. Future
longitudinal studies, designed to eval-
uate the typical time period for which
residual fetal cfDNA from vanishing
twins remains detectable, may provide
greater insight into appropriate clinical
care in these patients. -
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Confirmation methods for patients with diagnostic tests
Case Outcome Method
1 Triploidy CVS
2, 3, 4 Triploidy POC
5a Euploid Amniocentesis
6a Euploid CVS
7a Trisomy 18 CVS
CVS, chorionic villus sampling; POC, products of conception testing.
a Three nontriploid pregnancies that lacked evidence of co-twin demise.
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